Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer

Annals of Oncology

Volumn 21, Issue 6, 2009, Pages 1302-1307

  Khasraw, M ^a   Pavlakis, N ^a   McCowatt, S ^a,b   Underhill, C ^c   Begbie, S ^d   de Souza, P ^e   Boyce, A ^f   Parnis, F ^g   Lim, V ^a   Harvie, R ^a   Marx, G ^a,b  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b Clinical Trials Unit   (Australia)

^c Border Medical Oncology Australia   (Australia)

^d PORT MACQUARIE BASE HOSPITAL   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f Lismore Base Hospital ^*  (Australia)

^g Ashford Cancer Centre   (Australia)

Author keywords

Anti heparanase; Clinical trial; Docetaxel; PI 88; Prostate cancer; PSA response

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; DOCETAXEL; HEPARANASE INHIBITOR; PI 88; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; BETA GLUCURONIDASE; HEPARANASE; OLIGOSACCHARIDE; PHOSPHOMANNOPENTAOSE SULFATE; TAXOID;

ALOPECIA; ANOREXIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CASTRATION; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EPIPHORA; EPISTAXIS; EYE IRRITATION; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MULTICENTER STUDY; NAIL DISEASE; NAUSEA; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SKIN BRUISING; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; ADENOCARCINOMA; AGED; ANTAGONISTS AND INHIBITORS; CONTROLLED STUDY; DOSE RESPONSE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASTRATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCURONIDASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OLIGOSACCHARIDES; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT FAILURE;

EID: 77953974391     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp524     Document Type: Article

References (16)

1. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
2. Petrylak DP, Tangen CM, Hussain MHA et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
3. Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2002; 2: 521-528.
4. Vlodavsky I, Ilan N, Naggi A, Casu B. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 2007; 13(20): 2057-2073.
5. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006; 38(12): 2018-2039.
6. Parish CR, Freeman C, Brown KJ et al.; Identification of sulfated oligosaccharidebased inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 1999; 59: 3433-3441.
7. Demir M, Iqbal O, Hoppensteadt DA et al. Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88). Clin Appl Thromb Hemost 2001; 7: 131-140.
8. Pavlakis N, Monk R, Parish C. PI-88 demonstrates consistent positive interaction in combination with cisplatin, paclitaxel, vinorelbine, doxorubicin, 5-FU and gemcitabine in the BCI syngeneic rat adenocarcinoma model, 2002. In Proceedings of the 93rd Annual Meeting, American Association for Cancer Research (Abstr 1953).
9. Stordal B, Pavlakis N, Davey R. A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat Rev 2007; 33(8): 688-703.
10. Vlodavsky I, Abboud-Jarrous G, Elkin M et al. The impact of heparanase and heparin on cancer metastasis and angiogenesis. Pathophysiol Haemost Thromb 2006; 35(1-2): 116-127.
11. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17(11): 3461-3467.
12. Marx GM, Pavlakis N, McCowatt S. Phase II feasibility and efficacy study of three weekly docetaxel/prednisolone with thalidomide in androgen-independent prostate cancer. In ASCO Genitourinary Conference (Abstr 225). San Francisco, CA 2006.
13. Marx GM, Steer CB, Harper P et al. Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock!. J Clin Oncol 2002; 20: 1446-1448.
14. Lewis KD, Robinson WA, Millward MJ et al. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs 2008; 26(1): 89-94.
15. Beer TM, Lalani AS, Lee S et al. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer. Cancer 2008; 112(11): 2377-2383.
16. George DJ, Halabi S, Shepard TF etal. Theprognosticsignificanceofplasmainterlukin6 levels in patients with metastatic hormone-refractory prostate cancer: results from Cancer and Leukemia Group B 9480. Clin Cancer Res 2008; 11: 1815-1820.